Boston Strategics Corporation, an integrated research and development biotechnology company, has signed a new drug development partnership with Fujifilm Pharmaceuticals USA, Inc. (FPHU), a global pharmaceutical development centre of Japan based Fujifilm Corporation.
This strategic collaboration is the first of its kind between a Japanese pharmaceutical company and a pharmaceutical research and development provider, creating a novel and comprehensive approach to global pharmaceutical development.
Under this agreement, Boston Strategics will be the primary provider for FPHU global drug development services and resources for FPHU Oncology programs. This agreement will build on Boston Strategics strengths covering the spectrum from preclinical and early clinical development through Phase I and II human Proof-of-Concept (POC). Utilizing Boston Strategics’ internal oncology development expertise and ability to identify and collaborate with the best resources around the world, FPHU will expand its global reach in oncology drug development.
Boston Strategics will optimize and execute the global strategy of FPHU Oncology drug development programmes. In this capacity, Boston Strategics will leverage its “True Open Innovation” network to deliver superior outcomes, using highly efficient execution strategies and proven partners, such as the University of Texas MD Anderson Cancer Centre, Houston Texas (MD Anderson).
“True Open Innovation overcomes any limitations by reducing the need for large infrastructure, and draws on critical drug development expertise based on the unique needs of a particular programme,” says Keizo Koya, Ph.D., CEO of Boston Strategics. “Our strong business relationships with our global resource networks are poised to assist pharmaceutical/biotech companies with strategy and launch of quality global drug development programs, and rapidly execute them to the next decision step/value inflection point. We are deeply committed to giving a new pharmaceutical R&D platform for FPHU, which look for an innovative and efficient way of globally developing their unique oncology pipelines. Entering into a special alliance of Boston Strategics this year with MD Anderson, a world leader in cancer treatment and oncology research, Boston Strategics will use this opportunity to provide global clinical development supports for FPHU.”
The ultimate goal of this unique partnership is to develop Fujifilm’s oncology drug candidates globally using innovative approaches coupled with industry benchmark-beating timelines, quality, and financial investment.
Boston Strategics is an integrated biotechnology research and development company with experience in developing, managing and optimizing global drug development programs from late discovery, through translational research, first-in-man proof-of-concept studies.